Mesenchymal stem cells and uses therefor

• US 10,716,814 B2
• Filed: 11/30/2018
• Issued: 07/21/2020
• Est. Priority Date: 03/22/2004
• Status: Active Grant

• Current Assignee: Mesoblast International Srl
• Original Assignee: Mesoblast International SARL (Mesoblast Ltd.)
• Inventors: Aggarwal, Sudeepta, Pittenger, Mark F., Varney, Timothy
• Primary Examiner(s): Long, Scott
• Application Number:
  US16/206,235
• Publication Number:
  US 20190201447A1
• Time in Patent Office: 599 Days
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 5/0662 : Stem cells
• CPC Class Codes: C12N 5/0663 : Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 : Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 : Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 : Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims

1. A method of reducing inflammation in the gut, skin, or liver in a patient in need thereof comprising administering cultured mesenchymal stem cells to the patient in an amount effective to reduce the inflammation, wherein the mesenchymal stem cells are not genetically engineered with one or more polynucleotides encoding a therapeutic agent.

2. The method of claim 1, wherein the mesenchymal stem cells are allogeneic.

3. The method of claim 1, wherein the mesenchymal stem cells are autologous.

4. The method of claim 1, wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for inj ecti on.

5. The method of claim 1, wherein the mesenchymal stem cells are administered intravenously.

6. The method of claim 1, wherein the mesenchymal stem cells are administered intraarterially.

7. The method of claim 1, wherein the mesenchymal stem cells are administered in amount of about 1×

10⁵ cells/kg to about 5×

10⁷ cells per kg.

8. The method of claim 1, wherein the mesenchymal stem cells are administered in amount of about 1×

10⁶ cells/kg to about 5×

10⁶ cells per kg.

9. The method of claim 1, wherein the mesenchymal stem cells were isolated from marrow.

10. The method of claim 9, wherein the marrow is iliac crest marrow.

11. The method of claim 1, wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

12. The method of claim 2, wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection.

13. The method of claim 2, wherein the mesenchymal stem cells are administered intravenously.

14. The method of claim 2, wherein the mesenchymal stem cells are administered intraarterially.

15. The method of claim 2, wherein the mesenchymal stem cells are administered in amount of about 1×

10⁵ cells/kg to about 5×

10⁷ cells per kg.

16. The method of claim 2, wherein the mesenchymal stem cells are administered in amount of about 1×

10⁶ cells/kg to about 5×

10⁶ cells per kg.

17. The method of claim 2, wherein the mesenchymal stem cells were isolated from marrow.

18. The method of claim 17, wherein the marrow is iliac crest marrow.

19. The method of claim 2, wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

20. The method of claim 1, wherein inflammation in the gut is reduced.

21. The method of claim 1, wherein inflammation in the skin is reduced.

22. The method of claim 1, wherein inflammation in the liver is reduced.